Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 14/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3537546 | 0.84 | ACKR3 (0.58) | ACKR3MAPK1OPRK1 | |
| SCHEMBL3537544 | 0.84 | ACKR3 (0.58) | ACKR3MAPK1OPRK1 | |
| SCHEMBL3539290 | 0.81 | ACKR3 (0.59) | ACKR3ALDH1A1 | |
| SCHEMBL12410244 | 0.81 | ACKR3 (0.59) | ACKR3ALDH1A1 | |
| SCHEMBL3539292 | 0.81 | ACKR3 (0.59) | ACKR3ALDH1A1 | |
| SCHEMBL3539337 | 0.80 | ACKR3 (0.62) | ACKR3TNFRSF1A | |
| SCHEMBL3539339 | 0.80 | ACKR3 (0.62) | ACKR3TNFRSF1A | |
| SCHEMBL13166392 | 0.78 | ACKR3 (0.62) | ACKR3 | |
| SCHEMBL3540145 | 0.78 | ACKR3 (0.62) | ACKR3 | |
| SCHEMBL3540150 | 0.78 | ACKR3 (0.62) | ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144720-A1 | INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-7649011-B2 | Active against cancer proliferation, growth, and metastasis; such as 3,4,5-trimethoxy-n-(2-methyl-3-phenyl-allyl)-n-[2-(1-methyl-pyrrolidin-2-yl)-thyl]-benzamide; side effect reduction | CHEMOCENTRYX, INC. (US) | 2010-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144720-A1 | INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2 | CCL2, CCR2, CXCR2 | ACKR3 12/4885MAPK1 1883/4885OPRK1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.